Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

07 Oct 2019

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.

Bacteria — Summit thinks narrow-spectrum therapy is the best way to fight C. diff infections

Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

More from Clinical Trials

More from R&D